司妥昔单抗序贯沙利度胺联合环磷酰胺和泼尼松方案治疗特发性多中心型Castleman病一例

打开文本图片集

中图分类号：R552 文献标识码：B 文章编号：1000-503X（2025）03-0483-04

DOI：10.3881/j. issn.1000-503X.16284

Treatment of Idiopathic Multicentric Castleman’ s Disease With Sequential ThalidomideCyclophosphamide-Prednisone After Siltuximab： Report of One Case

DANG Yue¹，LI Jian¹，LUO Yaping²，ZHANG Lu1 1 Department of Hematology， 2 Department of Nuclear Medicine，PUMC Hospital，CAMS and PUMC，Beijing 100730，China

Corresponding author：ZHANG Lu Tel：O10-69155549，E-mail：pumczhanglu@126.com

ABSTRACT：Castleman’s disease is a rare polyclonal lymphoproliferative disorder.This article reports the diagnosisand treatment of a 45-year-old female patient with idiopathic multicentric Castleman’s disease.The patient presented recurrnt fever，enlarged lymph nodes，and elevated levelsof inflammation markers.After multiple serological examinationsand tissuebiopsies，she was diagnosedwith hyalinevascular-type Castleman's disease.Initiall，the patient received siltuximab targeting interleukin-6，which significantly improved her condition.Considering the cost and convenience of long-term treatment，she subsequently switched the therapy to an oraltreatment regimen of thalidomide，cyclophosphamide，and prednisone（TCP），which maintained disease control.This report aims to highlight the diagnosticcomplexityand diversityof treatment options for idiopathic multicentric Castleman’sdisease，demonstrating the potentialof the TCP regimenasacost-efective treatment choice.

KeyWords：Castleman’s disease；siltuximab；thalidomide，cyclophosphamide，and prednisone regimen

Castleman病（Castlemandisease，CD）是一种罕见的淋巴增殖性疾病，最初由Castleman教授于1954年报道[1]。（剩余7133字）